Cargando…

Securing the Chain of Custody and Integrity of Data in a Global North–South Partnership to Monitor the Quality of Essential Medicines

Substandard and falsified (SF) pharmaceuticals account for an estimated 10% of the pharmaceutical supply chain in low- and middle-income countries (LMICs), where a lack of regulatory and laboratory resources limits the ability to conduct effective post-market surveillance and allows SF products to p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayes, Kathleen, Meyers, Natalie, Sweet, Christopher, Ashenef, Ayenew, Johann, Tim, Lieberman, Marya, Kochalko, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Partners in Digital Health 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907419/
https://www.ncbi.nlm.nih.gov/pubmed/36779022
http://dx.doi.org/10.30953/bhty.v5.230
_version_ 1784884172006883328
author Hayes, Kathleen
Meyers, Natalie
Sweet, Christopher
Ashenef, Ayenew
Johann, Tim
Lieberman, Marya
Kochalko, David
author_facet Hayes, Kathleen
Meyers, Natalie
Sweet, Christopher
Ashenef, Ayenew
Johann, Tim
Lieberman, Marya
Kochalko, David
author_sort Hayes, Kathleen
collection PubMed
description Substandard and falsified (SF) pharmaceuticals account for an estimated 10% of the pharmaceutical supply chain in low- and middle-income countries (LMICs), where a lack of regulatory and laboratory resources limits the ability to conduct effective post-market surveillance and allows SF products to penetrate the supply chain. The Distributed Pharmaceutical Analysis Laboratory (DPAL) was established in 2014 to expand testing of pharmaceutical dosage forms sourced from LMICs; DPAL is an alliance of academic institutions throughout the United States and abroad that provides high-quality, validated chemical analysis of pharmaceutical dosage forms sourced from partners in LMICs. Results from analysis are reported to relevant regulatory agencies and are used to inform purchasing decisions made by in-country stakeholders. As the DPAL program has expanded to testing more than 1,000 pharmaceutical dosage forms annually, challenges have surfaced regarding data management and sample tracking. Here, we describe a pilot project between DPAL and ARTiFACTs that applies the blockchain to organize and manage key data generated during the DPAL workflow, including a sample’s progress through the workflow, its physical location, provenance of metadata, and lab reputability. Recording time and date stamps with these data will create a permanent and verifiable chain of custody for samples. This secure, distributed ledger will be linked to an easy-to-use dashboard, allowing stakeholders to view results and experimental details for each sample in real time and verify the integrity of DPAL analysis data. Introducing this blockchain-based system as a pilot will allow us to test the technology with real users analyzing real samples. Feedback from users will be recorded and necessary adjustments will be made to the system before the implementation of blockchain across all DPAL sites. Anticipated benefits of implementing the blockchain technology for managing DPAL data include efficient management for routing work, increasing throughput, creating a chain of custody for samples and their data in alignment with the distributed nature of DPAL, and using the analysis results to detect patterns of quality within and across brands of products and develop enhanced sampling techniques and best practices.
format Online
Article
Text
id pubmed-9907419
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Partners in Digital Health
record_format MEDLINE/PubMed
spelling pubmed-99074192023-02-10 Securing the Chain of Custody and Integrity of Data in a Global North–South Partnership to Monitor the Quality of Essential Medicines Hayes, Kathleen Meyers, Natalie Sweet, Christopher Ashenef, Ayenew Johann, Tim Lieberman, Marya Kochalko, David Blockchain Healthc Today Proof of Concept/Pilots/Methodologies Substandard and falsified (SF) pharmaceuticals account for an estimated 10% of the pharmaceutical supply chain in low- and middle-income countries (LMICs), where a lack of regulatory and laboratory resources limits the ability to conduct effective post-market surveillance and allows SF products to penetrate the supply chain. The Distributed Pharmaceutical Analysis Laboratory (DPAL) was established in 2014 to expand testing of pharmaceutical dosage forms sourced from LMICs; DPAL is an alliance of academic institutions throughout the United States and abroad that provides high-quality, validated chemical analysis of pharmaceutical dosage forms sourced from partners in LMICs. Results from analysis are reported to relevant regulatory agencies and are used to inform purchasing decisions made by in-country stakeholders. As the DPAL program has expanded to testing more than 1,000 pharmaceutical dosage forms annually, challenges have surfaced regarding data management and sample tracking. Here, we describe a pilot project between DPAL and ARTiFACTs that applies the blockchain to organize and manage key data generated during the DPAL workflow, including a sample’s progress through the workflow, its physical location, provenance of metadata, and lab reputability. Recording time and date stamps with these data will create a permanent and verifiable chain of custody for samples. This secure, distributed ledger will be linked to an easy-to-use dashboard, allowing stakeholders to view results and experimental details for each sample in real time and verify the integrity of DPAL analysis data. Introducing this blockchain-based system as a pilot will allow us to test the technology with real users analyzing real samples. Feedback from users will be recorded and necessary adjustments will be made to the system before the implementation of blockchain across all DPAL sites. Anticipated benefits of implementing the blockchain technology for managing DPAL data include efficient management for routing work, increasing throughput, creating a chain of custody for samples and their data in alignment with the distributed nature of DPAL, and using the analysis results to detect patterns of quality within and across brands of products and develop enhanced sampling techniques and best practices. Partners in Digital Health 2022-03-22 /pmc/articles/PMC9907419/ /pubmed/36779022 http://dx.doi.org/10.30953/bhty.v5.230 Text en © 2022 The Authors. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.
spellingShingle Proof of Concept/Pilots/Methodologies
Hayes, Kathleen
Meyers, Natalie
Sweet, Christopher
Ashenef, Ayenew
Johann, Tim
Lieberman, Marya
Kochalko, David
Securing the Chain of Custody and Integrity of Data in a Global North–South Partnership to Monitor the Quality of Essential Medicines
title Securing the Chain of Custody and Integrity of Data in a Global North–South Partnership to Monitor the Quality of Essential Medicines
title_full Securing the Chain of Custody and Integrity of Data in a Global North–South Partnership to Monitor the Quality of Essential Medicines
title_fullStr Securing the Chain of Custody and Integrity of Data in a Global North–South Partnership to Monitor the Quality of Essential Medicines
title_full_unstemmed Securing the Chain of Custody and Integrity of Data in a Global North–South Partnership to Monitor the Quality of Essential Medicines
title_short Securing the Chain of Custody and Integrity of Data in a Global North–South Partnership to Monitor the Quality of Essential Medicines
title_sort securing the chain of custody and integrity of data in a global north–south partnership to monitor the quality of essential medicines
topic Proof of Concept/Pilots/Methodologies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907419/
https://www.ncbi.nlm.nih.gov/pubmed/36779022
http://dx.doi.org/10.30953/bhty.v5.230
work_keys_str_mv AT hayeskathleen securingthechainofcustodyandintegrityofdatainaglobalnorthsouthpartnershiptomonitorthequalityofessentialmedicines
AT meyersnatalie securingthechainofcustodyandintegrityofdatainaglobalnorthsouthpartnershiptomonitorthequalityofessentialmedicines
AT sweetchristopher securingthechainofcustodyandintegrityofdatainaglobalnorthsouthpartnershiptomonitorthequalityofessentialmedicines
AT ashenefayenew securingthechainofcustodyandintegrityofdatainaglobalnorthsouthpartnershiptomonitorthequalityofessentialmedicines
AT johanntim securingthechainofcustodyandintegrityofdatainaglobalnorthsouthpartnershiptomonitorthequalityofessentialmedicines
AT liebermanmarya securingthechainofcustodyandintegrityofdatainaglobalnorthsouthpartnershiptomonitorthequalityofessentialmedicines
AT kochalkodavid securingthechainofcustodyandintegrityofdatainaglobalnorthsouthpartnershiptomonitorthequalityofessentialmedicines